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Dengue fever is currently ranked as the top emerging tropical disease, driven by
increased global travel, urbanization, and poor hygiene conditions as well as global
warming effects which facilitate the spread of Aedes mosquitoes beyond their current
distribution. Today, more than 100 countries are affected most of which are tropical
Asian and Latin American nations with limited access to medical care. Hence, the
development of a dengue vaccine that is dually cost-effective and able to confer a
comprehensive protection is ultimately needed. In this study, a consensus sequence
of the antigenic dengue viral glycoprotein domain III (cEDIII) was used aiming to
provide comprehensive coverage against all four circulating dengue viral serotypes
and potential clade replacement event. Utilizing hepatitis B tandem core technology,
the cEDIII sequence was inserted into the immunodominant c/e1 loop region so that
it could be displayed on the spike structures of assembled particles. The tandem
core particles displaying cEDIII epitopes (tHBcAg-cEDIII) were successfully produced
in Nicotiana benthamiana via Agrobacterium-mediated transient expression strategy to
give a protein of ∼54 kDa, detected in both soluble and insoluble fractions of plant
extracts. The assembled tHBcAg-cEDIII virus-like particles (VLPs) were also visualized
from transmission electron microscopy. These VLPs had diameters that range from 32 to
35 nm, presenting an apparent size increment as compared to tHBcAg control particles
without cEDIII display (namely tEL). Mice immunized with tHBcAg-cEDIII VLPs showed a
positive seroconversion to cEDIII antigen, thereby signifying that the assembled tHBcAg-
cEDIII VLPs have successfully displayed cEDIII antigen to the immune system. If it
is proven to be successful, tHBcAg-cEDIII has the potential to be developed as a
cost-effective vaccine candidate that confers a simultaneous protection against all four
infecting dengue viral serotypes.
Keywords: virus-like particles, epitope display, hepatitis B core antigen, dengue envelope glycoprotein, envelope
glycoprotein domain III, dengue vaccine, tandem core technology
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INTRODUCTION
The alarming rise of dengue epidemics has been highlighted to
affect over 40% of the world population (Brady et al., 2012).
The disease can be manifested as undifferentiated dengue fever
or life-threatening conditions such as dengue haemorrhagic
fever (DHF) and dengue shock syndrome (DSS) (Murrell
et al., 2011). Classified under the Flaviviridae virus family,
dengue virus (DENV) is a single-stranded, positive-sense non-
segmented RNA virus with 40–50 nm enveloped particles
(Guzman et al., 2010). The 10.6 kbp viral genome encodes a
polypeptide that is processed into structural proteins [capsid
(C); envelope glycoprotein (E); and precursor membrane (prM)]
and non-structural biomolecules (NS1, 2A, 2B, 3, 4A, 4B, and
5) (Henchal and Putnak, 1990). During virus assembly, the
C protein encapsidates the viral RNA to form nucleocapsid
particles whereas the prM assists the folding of surface-exposed
E glycoprotein (Whitehead et al., 2017). Transmission of the
endemic virus has been observed in over 100 countries. The
incidence rate has expanded 500-fold, spreading from South-
east Asia to the Americas and Western Pacific within just a-half
century (Pang and Loh, 2016). Global distribution of dengue
disease is strongly influenced by urbanization, demographic,
and environmental factors including global warming which
has enabled Aedes mosquitoes to survive beyond their usual
distribution. Concerns are also driven by increasing movement
of travelers (Pang and Loh, 2016). The annual incidence has
grown dramatically in recent decades, in which 390 million
cases are predicted per annum and 96 million amongst these
cases manifest an apparent clinical or sub-clinical severity (Bhatt
et al., 2013). Out of these, it was reported that 500,000 people
were hospitalized with severe dengue and approximately 2.5% of
them would succumb to the disease (World Health Organization
[WHO], 2017). The reported figure may be under-estimated due
to the passive surveillance system adopted by many countries
(Runge-Ranzinger et al., 2014).
To date, no specific medication is available for dengue
treatment. Current clinical practices mainly rely on
administration of paracetamol and intravenous fluid, together
with close monitoring of the haematocrit and platelet levels
(Anfasa et al., 2015). The absence of specific drugs and lack of
confidence in currently marketed vaccines have also driven the
public’s reliance on folk remedies that are yet to be scientifically
proven. Thus, development of a dengue vaccine is still being
aggressively pursued to address the unmet medical needs of
people in tropical regions (Pang and Loh, 2017). For subunit
vaccine production, the dengue E glycoprotein has been the most
studied antigenic determinant. Its structure is organized into
three ectodomains (EDIII), and serves to assist attachment and
entrance into host cells via receptors (Faheem et al., 2011). The
immunoglobulin-like domain III (EDIII) is an ideal immunogen
as it harbors receptor binding motifs that can elicit neutralizing
monoclonal antibodies production (Crill and Roehrig, 2001). In
recent years, EDIII has been expressed as a consensus sequence
(cEDIII) aligned between four DENV serotypes (Chiang et al.,
2011; Kim et al., 2012, 2015, 2016, 2017; Huy and Kim, 2017).
A proof-of-concept study showed that cEDIII could inhibit the
infectivity of four dengue serotypes simultaneously following
mice immunization (Leng et al., 2009). Therefore, this sequence
was adopted with the aim of conferring protection against all
four co-circulating dengue serotypes.
Virus-like particles (VLPs) have gradually emerged as vaccine
delivery vehicles that are spontaneously assembled from viral
structural proteins. These are multimeric structures that can
directly stimulate immune cells by mimicking the three-
dimensional conformation of native viruses. Moreover, VLPs
are devoid of infectious genetic material which makes them
inherently safer than attenuated or inactivated virus preparations
(Pang, 2018). VLPs are known to elicit higher B- and T-cell
immune responses and hence lower dosage is usually sufficient
(Gamvrellis et al., 2004; Roy and Noad, 2008). The repetitive
array of protein subunits in VLPs has the potential to confer
superior properties as a stand-alone vaccine when compared to
those of recombinant subunit-based ones which may be weak
immunogens despite the use of an adjuvant (Noad and Roy,
2003). All these features make VLPs a premium platform for the
production of a safe and effective vaccine (Jain et al., 2015).
In this study, hepatitis B core antigen (HBcAg) was exploited
for cEDIII epitope display. Early work on HBcAg was done
by Clarke et al. (1987) to produce foot and mouth disease
virus fusion particles with proven serological response in guinea
pigs. The icosahedral VLPs are shaped by association of two
HBcAg monomers into 90 (T = 3) or 120 (T = 4) dimers, with
a hairpin structure bridged by c/e1 loops to form protruding
spike (Crowther et al., 1994). The flexibility of inserting foreign
sequence into the immunodominant c/e1 loop for surface
exposure, while retaining its antigenic properties, is ideal for
antigen presentation (Pumpens and Grens, 1999). In fact,
insertion in the c/e1 region was shown to impart a stronger
protective response compared to N- and C-terminal fusions to
the core particles (Koletzki et al., 2000). Thus, the cEDIII gene
was incorporated into the c/e1 loop for the benefit of maximized
exposure on protruding spikes of the assembled VLPs. “Tandem
Core” technology was adopted here to produce the chimeric
HBcAg VLPs. It has been shown that this technology which
covalently links two core proteins into dimer forms (Peyret
et al., 2015) can alleviate potential steric hindrance between two
inserts at each immunodominant c/e1 loop of the dimer interface
and thus promotes chimeric VLP assembly. This technology has
recently been applied successfully to make other viral vaccine
candidates (Ramirez et al., 2018).
In the context of molecular pharming, plants have certain
advantages when compared to bacterial and animal expression
systems relating to lower production cost, rapid scalability,
biocontainment warranty, and eukaryotic processing machinery
(Sack et al., 2015; Tschofen et al., 2016; Loh et al., 2017). The
emergence of transient expression systems has ultimately sped
up the process, whereby rapid candidate screening and large-
scale production are achievable within days (Thuenemann et al.,
2013). Moreover, there is evidence that plants may be a better
choice than bacteria for the production of tandem core-based
VLPs (Peyret et al., 2015). This study aimed to demonstrate
the production of chimeric HBcAg particles displaying dengue
cEDIII epitopes (tHBcAg-cEDIII) using a plant-based system,
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with the hope of developing a novel VLP-based vaccine against
the deadly dengue disease. Given that DENV clade replacements
had been detected in recent years (Teoh et al., 2013), the
development of a vaccine that can provide a consistent protection
in the long run will be highly valued (Pang, 2018). Moreover,
generating a vaccine based on the single consensus cEDIII
antigen should reduce the underlying cost as it obviates the
need to test the best tetravalent formulation from monovalent
components of each DENV serotype.
MATERIALS AND METHODS
Recombinant Vector Construction
The 103 amino acid residues of cEDIII consensus sequence
used (see Supplementary Material) were based on the
alignment of four DENV serotypes as described by Leng
et al. (2009). The synthesized gene sequence of cEDIII
was codon-optimized (GeneArt, United States) for the
expression in Nicotiana benthamiana. Primers were
designed to incorporate AvrII and Sbf I restriction sites
(underlined) at 5′ and 3′ ends of the cEDIII gene (cED3F: 5′-
GAATACCTAGGAAGGGAATGTCATACGCTATGTGTACTG
GAAAG-3′; cED3R: 5′-CATTGCCTGCAGGTGAAGATCCCT
TCTTGAAC-3′) for sub-cloning into pEAQ-HT::tHBcAg-
VHH2, a plasmid derived from pEAQ-τGFP (GenBank accession
number KM396759, Peyret et al., 2015) which contains long
glycine-rich linkers [(GGS)n] with unique restriction sites at the
c/e1 loop region of the downstream second core (Core II) for ease
of cloning. Following heat-shock transformation of competent
Escherichia coli, putative clones harboring the expression
vector (pEAQ-HT::tHBcAg-cEDIII) were screened and verified
by sequencing (Eurofins, Germany). Figure 1 illustrates the
expression cassette and corresponding recombinant vector used
in this study. Additional information on the construct sequence
can be found in the Supplementary Material.
Agrobacterium tumefaciens
Transformation and Plant Infiltration
Nicotiana benthamiana plants were grown on custom-mixed soil
comprising of peat, 2.5 kg/m3 dolomite limestone, 1.3 kg/m3
base fertilizer, 2.7 kg/m3 Osmocote R© (applied every 3–4 months),
0.3 kg/m3 Exemptor R©, and 0.25 kg/m3 wetter in a controlled
environment of 16-h photoperiod generated by 400 W sodium
lamps, 24◦C and 70% relative humidity. Plants at 5–6 weeks
old (until they reached the pre-flowering stage) were used in
the study. The recombinant vector, pEAQ-HT::tHBcAg-cEDIII
was introduced into Agrobacterium tumefaciens strain LBA4404
via electroporation. Transformed colonies were then selected
from agar plates supplemented with 50 µg/ml kanamycin and
50 µg/ml rifampicin. The protocol from Sainsbury et al. (2012)
was adopted here. Agrobacterial suspensions were cultured at
28◦C in a shaking incubator (200 rpm) for 24–48 h. The
agrobacterial cells were harvested by 4,000 × g centrifugation
for 10 min and resuspended in MMA solution [10 mM
MES (2-[N-morpholino]ethanesulfonic acid) at pH 5.6, 10 mM
MgCl2 and 100 µM acetosyringone] to a final OD600 of 0.4.
The abaxial side of the developed N. benthamiana leaves was
pricked and infiltrated with the agrobacterial suspensions using a
needleless syringe. Time-course evaluation of the selective leaves
of infiltrated plants was performed until 9 days post-infiltration
(dpi). Control agrobacterial suspensions containing the empty
pEAQ-HT vector (Sainsbury et al., 2009) without a gene insert
was included to compare with pEAQ-HT::tHBcAg-cEDIII for
physical observation of plants post-infiltration.
Protein Extraction
Small-scale extraction was conducted to test for protein
expression and accumulation. Approximately 100 mg of the
infiltrated leaf was harvested and homogenized with a 1⁄4-inch
ceramic bead (MP Biomedicals, United States) in 3× volume
of extraction buffer [100 mM sodium phosphate at pH 6.8,
150 mM NaCl, 0.1% Triton-X and protease inhibitors (Roche,
Switzerland)]. The Omni Bead Ruptor 24 homogeniser (Camlab,
United States) was adjusted at speed setting 4 for 30 s for tissue
homogenization. Samples were then centrifuged at 16,000 × g
for 10 min and the supernatant was kept as soluble protein (SP)
fraction. Nevertheless, insoluble protein (IP) fraction could be
extracted from the pellet through boiling with protein denaturing
buffer [NuPAGE LDS buffer (Life Technologies) mixed 3:1
with 2-mercaptoethanol] and centrifugation at 16,000 × g for
10 min. To check for protein integrity, sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) was conducted
at 200 V for 50 min and stained with InstantBlue (Expedeon,
United Kingdom).
For large-scale extraction, infiltrated leaves were excised,
weighed and homogenized with 3× volume of the same
extraction buffer in a Waring blender. Crude extracts were
filtered through a layer of Miracloth before subjecting to
centrifugation (20,000 × g) at 4◦C for 20 min using an SS34
rotor (Thermo Fisher Scientific, United States). The clarified
supernatant was filtered over 0.45 µm syringe filters prior to
subsequent purification procedures.
Purification of Virus-Like Particles (VLPs)
Virus-like particles samples were subjected to a two-stage
purification process as described by Peyret (2015). Firstly,
clarified extracts were overlain above different concentrations
of sucrose solution; specifically 6 ml of 25% (w/v) and
2 ml of 70% (w/v). Double-layered sucrose cushions were
prepared in UltraClear ultracentrifuge tubes (Beckman Coulter,
United States) and centrifuged in a Surespin 630/36 swing-out
rotor (Thermo Fisher Scientific, United States) at 167,000 × g,
4◦C for 2.5 h. The gradient was fractionated by piercing the
bottom of the tube with a needle and recovering the bottom
and interface fractions. These fractions were then dialyzed
thoroughly against 200 mM ammonium bicarbonate buffer (pH
8.0) overnight. Next, samples were concentrated using SpeedVac
(Thermo Fisher Scientific, United States), and loaded onto a
Nycodenz step gradient extending from 60 to 20% (w/v), with
2 ml of each concentration in UltraClear ultracentrifuge tubes
(Beckman Coulter, United States). High-speed centrifugation was
operated at 274,000 × g using the TH-641 swing-out rotor
(Thermo Fisher Scientific, United States) for 20 h at 4◦C. Bottom
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FIGURE 1 | A schematic illustration of the recombinant vector, pEAQ-HT::tHBcAg-cEDIII. The cEDIII gene sequence was specifically inserted into the Core II c/el
loop. The pEAQ-HT vector used in this study was based on Sainsbury et al. (2009), and the amino acid sequence of tHBcAg-cEDIII is shown in the
Supplementary Material.
of the tubes was punctured with a needle and divided into
successive fractions. These fractions were assayed with Western
blotting to determine the distribution of the desired particles.
Purification of cEDIII Protein
Recombinant cEDIII protein was used in this study as an
antigen positive control for immunization work. In brief,
the plant-expressed protein was harvested at 6 dpi following
agroinfiltration with pEAQ-HT::PR1a-cEDIII-sGFPH-KDEL
(Pang, 2018). As the recombinant protein was produced as
a cleavable fusion to green fluorescent protein (sGFP) with
a histidine tag, first-step isolation was achieved via native
immobilized metal affinity chromatography (IMAC) (agarose
resin derivatized with nickel ion-nitrilotriacetic acid; Qiagen,
Germany). Following AcTEVTM protease digestion (Thermo
Fischer Scientific, United States), the final product (cEDIII
alone) was harvested from the flow-through fraction of a second
IMAC procedure. The cEDIII protein was dialysed against
phosphate-buffered saline (PBS) prior to the downstream testing.
Western Blotting Analysis
For immunoblotting analysis, the electrophoresed proteins were
electroblotted onto a nitrocellulose membrane (GE Healthcare,
United States) via wet transfer at 100 V for 1 h. Blotted membrane
was blocked with 5% (w/v) milk powder in PBS containing
0.05% (v/v) Tween-20 (PBST) for at least 1 h. The membrane
was subsequently incubated with either mouse anti-HBcAg
monoclonal antibody (10E11; Abcam, United Kingdom) (1:4,000
dilution) or mouse anti-DENV 1–4 monoclonal antibody [D1-
11(3); Thermo Fisher Scientific, United States] (1:2,000 dilution)
for 1 h. Then, the membrane was washed three times with PBST at
5-min intervals before incubation with mouse immunoglobulin
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G (IgG) horseradish peroxidase (HRP)-conjugated secondary
antibody (M30107; Invitrogen, United States) (1:10,000 dilution).
Washing steps were repeated three times before the blot
was soaked in chemiluminescence solution and detected using
ImageQuant LAS 500 (GE Healthcare, United States).
Transmission Electron Microscopy
(TEM) Examination
All VLP samples (tHBcAg-cEDIII) were dialyzed against PBS
using Float-A-Lyzer (Sigma, United States). Approximately 10 µl
of the VLPs sample was adsorbed onto copper-palladium grids,
washed with sterile distilled water and negatively stained with
2% (w/v) uranyl acetate. As an experimental control, the tandem
core particles without gene insert (tEL, Peyret et al., 2015) was
also examined. Both particles (tHBcAg-cEDIII and tEL) were
viewed using the FEI Tecnai 20 transmission electron microscope
(FEI, United States).
Protein Quantification
Pierce modified Lowry protein assay kit was used according
to the manufacturer’s instruction (Thermo Fisher Scientific,
United States) for protein quantification. The absorbance of
sample replicates and diluted albumin standards was then
measured at 750 nm using CLARIOstar microplate reader (BMG
LABTECH, Germany). The purified tHBcAg-cEDIII VLPs were
also analyzed by SDS-PAGE (refer to Supplementary Figure S1
for this SDS-PAGE profile).
Mouse Immunization
Two independent animal immunization experiments were
conducted using female BALB/c mice (Envigo, United Kingdom)
at 6–8 weeks old. For each experiment, at least four mice
per group were immunized with 5 µg of purified VLP
particles containing the cEDIII antigen insert (tHBcAg-cEDIII)
mixed with 50 µl of Imject Alum (Thermo Fisher Scientific,
United States) in a final volume of 100 µl made up by sterile
saline solution. As a positive control group for cEDIII antigen,
mice were immunized with 5 µg of recombinant cEDIII protein
purified by using nickel ion-nitrilotriacetic acid agarose resin
(Qiagen, Germany). Another group of mice was immunized
with 5 µg of empty VLPs without cEDIII insert (tEL), which
served as a negative control for cEDIII antigen. In addition,
there was another control group of mice were injected with
100 µl of sterile normal saline solution. Three immunizations
were delivered intra-peritoneally, administered 1 week apart. Tail
bleeds were performed to check for seroconversion 4 weeks after
primary immunization, and terminal bleeds at the completion of
experiment at 9 weeks post-immunization. All animal works were
done in compliance with United Kingdom Home Office approved
animal protocols under license PPL 70/7376.
Enzyme-Linked Immunosorbent
Assay (ELISA)
Detection of antigen-specific IgG antibodies was performed
by ELISA. Briefly, 96-well Nunc Maxisorp plates (Sigma,
United States) were coated with 1 µg/ml pure cEDIII protein
in carbonate bi-carbonate buffer overnight at 4◦C. Coated plates
were washed three times with PBS-Tween 20 (0.05% v/v) and
blocked with 10% skimmed milk solution (Sigma, United States)
for 1 h at 37◦C. Primary sera were serially diluted (twofold)
in 2.5% (w/v) milk solution from 1:100 to 3,200. All samples
were added to duplicate test wells, incubated at 37◦C for 1 h
then washed three times as mentioned before. Goat-anti-mouse
IgG-peroxidase secondary antibody was added at 1:2,500 dilution
(Sigma, United States) and incubated at 37◦C for 1 h then washed
three times again. 3, 3′, 5, 5′-Tetramethylbenzidine substrate
(Sigma, United States) was added to each well for 20 min and
reaction was stopped with 1M H2SO4. Absorbance at 450 nm
with a 630 nm correction was read using the SpectraMAX
190 plate reader (Molecular Devices, United States). Unpaired
Student’s t-test was conducted to compare the immunization
groups of mice receiving either recombinant cEDIII protein
or tHBcAg-cEDIII VLPs against the empty tandem core VLPs
control (tEL) in order to determine the significance level of
cEDIII-specific IgG produced. The significant difference of
cEDIII-specific IgG levels between cEDIII and tHBcAg-cEDIII
groups was also compared. The significance levels were denoted
at p ≤ 0.001 with ∗∗ and p ≤ 0.0001 with ∗∗∗ in the graph.
RESULTS
Expression of Recombinant
tHBcAg-cEDIII Construct
in N. benthamiana
Following agroinfiltration, N. benthamiana leaves were collected
on 6 dpi and analyzed by Western blotting technique to check
for expression. Western profiles indicated that the tHBcAg-
cEDIII proteins had been expressed well in N. benthamiana
infiltrated with pEAQ-HT::tHBcAg-cEDIII (Figure 2), based
FIGURE 2 | Expression profiles of tHBcAg-cEDIII protein in N. benthamiana
analyzed at 6 dpi, which was predominantly obtained in insoluble form.
Immunoblot detection of tHBcAg-cEDIII proteins at ∼54 kDa in size (black
arrow) was performed using anti-HBcAg monoclonal antibody. Lane M:
SeeBlue R© Plus2 Pre-Stained Standard; Lane 1: SP extracted from
pEAQ-HT::tHBcAg-cEDIII-infiltrated leaf disks; Lane 2: IP extracted from
pEAQ-HT::tHBcAg-cEDIII-infiltrated leaf disks; Lane 3: SP extracted from
pEAQ-HT-infiltrated leaf disks; Lane 4: IP extracted from pEAQ-HT-infiltrated
leaf disks.
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on the band at around 54 kDa which was not present in the
pEAQ-HT-infiltrated plant leaf sample. However, the yield of
soluble tHBcAg-cEDIII (SP) was very low (barely detectable)
compared to the insoluble tHBcAg-cEDIII (IP) fraction. It was
estimated that over 90% of the tHBcAg-cEDIII produced by the
plant was insoluble.
Kinetic Expression and
Physical Observations on the
Infiltrated N. benthamiana
A time-course evaluation was performed to determine the
optimal harvest time of tHBcAg-cEDIII protein for subsequent
extraction and purification procedures. In general, symptoms
of leaf chlorosis were observed from 7 dpi onward in
all pEAQ-HT::tHBcAg-cEDIII-infiltrated plants, which led to
visible necrosis by 9 dpi. This leaf chlorosis symptom was
not observed with the empty vector, pEAQ-HT-infiltrated
plants. A representative series of a pEAQ-HT::tHBcAg-cEDIII-
infiltrated leaf is shown in Figure 3A. Concurrently, infiltrated
leaves were harvested on a daily basis to monitor the
accumulation of soluble proteins. As illustrated in Figure 3B,
increasing amounts of tHBcAg-cEDIII SP could be seen
from 6 dpi onward. As advanced necrosis was observed on
9 dpi in these infiltrated plants, it was deemed sensible to
set 8 dpi as the optimal harvest time for soluble tHBcAg-
cEDIII protein.
Purification of Chimeric Tandem Core
Particles Displaying cEDIII Epitopes
Leaves infiltrated with the recombinant vector, pEAQ-
HT::tHBcAg-cEDIII were harvested on 8 dpi for large-scale
purification. The first isolation step via sucrose cushion yielded
70% sucrose and interface fractions, which were collected for
maximal recovery of VLPs present in the sample (Figure 4A).
Further purification by Nycodenz gradient gave rise to a
single grayish band (Figure 4B). From here, the band was
separated from the sedimentation of green impurities toward
the top of the gradient. The single band was confirmed to be
tHBcAg-cEDIII VLPs distribution following Western blotting
analysis (Figure 4C), with sedimentation point estimated at
around 40% Nycodenz concentration. The yield of purified
tHBcAg-cEDIII VLPs was in the range of ∼12–16 mg/kg,
which is comparable to that of purified recombinant cEDIII
(∼13–14 mg/kg).
Following the purification process, TEM imaging analysis
revealed that plant-produced tHBcAg-cEDIII assembled into
VLPs (Figure 5A), which were visualized as a mixture of core-
like particles of slightly different sizes. These particles exhibited
an irregular spherical morphology that characterizes tandem core
particles displaying a heterologous sequence in the c/e1 loop.
The diameters of these particles ranged from 32 to 35 nm, with
an average particle size of ∼34 nm. As illustrated in Figure 5B,
purified tEL sample (empty tandem core VLPs without insert)
formed smaller, more evenly sized particles, with an average size
of∼27 nm in diameter. Comparatively, tHBcAg-cEDIII particles
appeared to be somewhat larger than the empty tEL particles.
FIGURE 3 | Kinetic study of pEAQ-HT::tHBcAg-cEDIII-infiltrated
N. benthamiana. (A) Physical appearances of the representative infiltrated leaf
from 1 to 9 dpi. (B) Expression profiles of the corresponding tHBcAg-cEDIII
proteins (∼54 kDa; black arrow) which were immunoblotted with anti-HBcAg
monoclonal antibody. Lane M: SeeBlue R© Plus2 Pre-Stained Standard; Lanes
1–9: SP extracted from infiltrated N. benthamiana from 1 to 9 dpi,
correspondingly. It was decided that 8 dpi to be the suitable harvest time for
soluble tHBcAg-cEDIII protein.
Immunogenicity of Chimeric Tandem
Core Particles Displaying cEDIII Epitopes
The seroconversion results in BALB/c mice immunized with the
VLP-based dengue vaccine candidate are presented in Figure 6.
cEDIII-specific IgG antibody was successfully detected in mice
immunized with tHBcAg-cEDIII VLPs and recombinant cEDIII
protein alone. However, the IgG antibody level elicited by the
recombinant cEDIII protein alone was higher than that of
tHBcAg-cEDIII VLPs at all 1:100 to 1:3,200 dilutions tested
(Figure 6A). The control groups (normal saline and tEL) did
not trigger any cEDIII-specific IgG antibody responses and this
observation has indicated the absence of pre-exposure of DENV
(cEDIII). Figure 6B shows that cEDIII-specific IgG antibody level
elicited by tHBcAg-cEDIII VLPs was significantly higher than
that of the negative control, tEL-immunized mice (p ≤ 0.0001 at
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FIGURE 4 | Sucrose cushion and Nycodenz gradient fractionation of proteins extracted from pEAQ-HT::tHBcAg-cEDIII-infiltrated leaves. (A) Western blot profiles
showing the desired tHBcAg-cEDIII VLPs (black arrow) were successfully detected using anti-HBcAg monoclonal antibody. Lane M: SeeBlue R© Plus2 Pre-Stained
Standard; Lane 1: Clarified plant lysate; Lane 2: 70% sucrose fraction; Lane 3: Interface fraction. (B) A single grayish band along the Nycodenz gradient that can be
visualized. (C) Western blot profiles of Nycodenz gradient fractions detected using anti-DENV 1–4 monoclonal antibody. Lane 1: 60% Nycodenz fraction; Lane 2:
50% Nycodenz fraction; Lane 3: 40% Nycodenz fraction; Lane 4: 30% Nycodenz fraction; Lane 5: 20% Nycodenz fraction. As indicated by the black arrow, desired
tHBcAg-cEDIII VLPs were successfully recovered from the infiltrated N. benthamiana.
week 4 and week 9). However, when comparing between cEDIII
and tHBcAg-cEDIII groups, the specific IgG level of cEDIII-
immunized group mice was in fact significantly higher (p≤ 0.001
at week 4 and p ≤ 0.0001 at week 9). In general, our data
showed that IgG antibody levels appeared to peak after 4-week
post-immunization, then began to wane but were still detectable
more than 2 months after immunization. These results suggest
that the cEDIII antigen inserted into the c/e1 loop of tandem
core particles was still immunogenic and able to elicit a specific
humoral response.
DISCUSSION
Development of VLPs as a highly structured form of subunit
vaccine has been increasingly explored in recent years, whereby
they present themselves as multimeric structures that mimic
native virions. Production of dengue VLPs had been attempted
previously (Sugrue et al., 1997; Liu et al., 2010; Zhang et al., 2011;
Mani et al., 2013); however, several shortfalls were identified
such as the neutralizing antibody responses acquired by mice
were generally weak and co-expressing the DENV prM and
EDI/EDII can trigger antibody-dependent enhancement (ADE)
phenomenon. This is where pre-existing, non-neutralizing
antibodies from an initial DENV infection can bind with the
new infecting serotype and infect Fc gamma receptor (FcγR)-
bearing cells to gain entry into host cells (Bäck and Lundkvist,
2013). Hence, ADE is often affiliated with disease aggravation and
known to be the strongest risk factor of DHF/DSS development
(Kliks et al., 1989). Therefore, generating a durable immunity
against all four serotypes of DENV by using serotype-specific
VLPs would require the expression of four monovalent VLPs
together in the optimal tetravalent formulation, which would
represent a significant technical challenge.
Because of this, the rationale for the work presented here was
to produce chimeric VLPs which are able to self-assemble while
presenting a consensus DENV antigen on their surfaces. In this
study, the VLPs derived from HBcAg were utilized for cEDIII
epitope display. As the stand-alone stability of DENV domain III
has made it intrinsically different from other parts of the E protein
(Soares and Caliri, 2013), it is believed that cEDIII can behave as
an independent entity and would not interrupt the assembly of
viral particles (Pang, 2018). The resulting chimeric HBcAg VLPs
are therefore expected to display a high density of cEDIII epitopes
on 90 or 120 copies of core protein dimers per particle.
In this study, “Tandem Core” technology was adopted due to
the concern that two copies of cEDIII inserts at HBcAg dimer
interface might suffer from steric clashes which could abrogate
particle assembly. Thus, it is anticipated that this strategy could
resolve the steric constraints as VLPs are now assembled from
the dimers of HBcAg protein, expressed from a single open
reading frame coding for two copies of HBcAg that have been
covalently linked (Peyret et al., 2015). The cEDIII gene was
inserted into the immunodominant c/e1 loop of Core II (the
C-terminal copy of HBcAg), so that this would minimize the
disruption to VLPs assembly as the translation moved in 5′
→ 3′ direction from the unmodified Core I. With this, the
tandem core would have greater flexibility as only one of the two
c/e1 loops on each dimer was decorated with cEDIII antigens
(Pang, 2018).
The cEDIII gene expressed in this study was codon-optimized
based on N. benthamiana preference to boost translation by re-
coding the rare codon in foreign gene with synonymous codon
preferred by the expression host (Angov, 2011). Apart from
that, a glycine and serine-rich linker was designed to avoid
spurious interaction between the cEDIII inserts and core protein
subdomains: this linker consisted of 15 amino acids on either
side of the cEDIII insert (the exact sequence is shown in the
Supplementary Material). As this approach was shown to be
useful by Kratz et al. (1999), it was hoped that the (GGS)n
linkers can help to minimize the steric constraints and stabilize
the chimeric HBcAg VLPs expressing the cEDIII epitopes (Pang,
2018). Indeed, these linkers allowed the display of a nanobody
protein inserted in Core II of plant-produced tandem cores
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FIGURE 5 | Electron micrographs showing the purified tandem core
tHBcAg-cEDIII and tEL VLPs that were negatively stained with 2% (v/v) uranyl
acetate. (A) tHBcAg-cEDIII VLPs visualized at 50,000× magnification.
(B) Negative control tEL VLPs visualized at 50,000× magnification. Scale bar
represents 100 nm. The chimeric tHBcAg VLPs with cEDIII epitopes had
successfully assembled into viral particles.
(Peyret et al., 2015). Nevertheless, the length of the linkers was not
optimized in the context of this work, and it is possible that higher
yield and better solubility could be achieved upon optimization.
Based on the kinetic expression studies (Figure 3), it is
postulated that the chimeric VLP construct does not confer
significant toxicity to plants as early necrosis or apoptosis was
not evident. The profiles were useful to gauge the ideal harvest
time which is assessed based on the peak accumulation of soluble
target protein, and the post-infiltration morphological distortions
of the leaves. Necrotic tissues are usually avoided as they are
flaccid and may contain higher amount of phenolics that could
be introduced into downstream processing (Tanguy and Martin,
1972). In fact, the antimicrobial exudate produced by necrotic
tissues can inhibit efficient colonization and gene delivery by
Agrobacterium (Pitzschke, 2013). In this case, the optimal harvest
time for the chimeric tHBcAg-cEDIII VLPs was determined to
be around 8 dpi. A constant OD600 of 0.4 for the agrobacterial
infiltration suspension was used throughout this study in line
with the recommended range of OD600 at 0.3–0.4 as reported
previously (Li, 2011; Pua et al., 2012; Shamloul et al., 2014). This
is because high bacterial density tends to trigger hypersensitive
response that can lead to tissue necrosis, whereas low amount of
Agrobacterium may result in insufficient gene delivery (Leuzinger
et al., 2013). As presented in this study, an acceptable level of
transient gene expression was achieved at the chosen OD600 of
0.4, without severely triggering the hypersensitivity responses
(Pang, 2018).
To purify the VLPs of interest, the procedures begin with a
discontinuous two-step sucrose cushion to enrich the isolation
of core particles from clarified lysate in a fast and reproducible
manner (Peyret, 2015). After that, an additional isopycnic
gradient was applied to complement the earlier technique in
preparation of high purity particles (Brakke, 1961). Generally,
Nycodenz is an inert chemical that can generate a self-forming
gradient (Gugerli, 1984) and it worked well for the purification of
tHBcAg-cEDIII VLPs as evidenced in Figure 4. TEM observation
revealed that the assembly of particles was successful (Figure 5A).
Instead of being uniformly shaped, tHBcAg-cEDIII particles
appeared to be rather “knobbly” due to the epitopes protruding
from HBcAg spikes. These VLPs, which ranged from 32 to 35 nm
in diameter are somewhat larger than their empty counterpart
labeled as tEL (Figure 5B). This type of surface morphology
is in fact expected for tandem core particles displaying a
heterologous sequence on their surface (Peyret et al., 2015).
Such finding indicates that cEDIII epitopes were presented on
the protruding spikes of HBcAg that retained the inherent
propensity to fold into discrete VLPs. In fact, the size range
of 35–40 nm for chimeric HBcAg VLPs with dengue EDIII
epitopes produced in microbial cells, was previously reported
by Arora et al. (2012, 2013).
To our knowledge, this is the first study that reports the
successful production of chimeric HBcAg VLPs with dengue
protein epitopes in a plant system. It was shown that the
cEDIII epitopes remain immunogenic when presented on
the VLP scaffold (HBcAg-cEDIII): the specificity of the IgG
responses detected is demonstrated by the lack of cEDIII-
reactive antibodies in the saline control and empty tHBcAg (tEL)
groups (Figure 6). The specific IgG antibody levels induced
by both HBcAg-cEDIII VLPs and recombinant cEDIII (positive
control) were higher at week 4 post-immunization and declined
thereafter as detected at week 9, which is consistent with the
kinetics of a normal immune response (Leo et al., 2011). As
the ELISA plates were coated with purified cEDIII protein, it
is possible that the higher IgG antibody level detected in the
recombinant cEDIII group could be due to an optimum antigen-
antibody match as compared to that of tHBcAg-cEDIII group.
Additionally, the low antibody response (tHBcAg-cEDIII) could
also be explained by the lower molar antigen dose received
by the HBcAg-cEDIII-immunized mice as the antigen dose for
immunization was normalized to a total protein concentration
of 5 µg. Therefore, the actual dosage of cEDIII on the VLPs
is much lower (in molar terms) than the subunit recombinant
proteins. The tHBcAg-cEDIII is composed mainly of tHBcAg
carrier by protein mass, and cEDIII only contributes to 103
out of the total 508 amino acids. Taken the suggestion of
Whitacre et al. (2016), the amount of cEDIII presented in
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FIGURE 6 | Evaluation of cEDIII-specific IgG antibody responses in BALB/c mice by using ELISA. (A) cEDIII-specific IgG antibody levels of mouse sera at the
dilutions from 1:100 to 1:3,200 following 4- and 9-week post-immunizations. (B) Comparison of mouse antibody responses following 4- and 9-week
post-immunizations as tested by ELISA at the dilution of 1:100. Bars represent the mean ± standard error of mean and the graphs are representative of two
independent animal immunization experiments (n = 2). Student’s t-test was used to determine the significance levels (p ≤ 0.001 denotes as ∗∗ and p ≤ 0.0001
denotes as ∗∗∗). Note that a indicates the comparison between the immunization groups of mice receiving cEDIII (positive control) against empty VLPs (tEL; negative
control); b indicates the comparison between tHBcAg-cEDIII and tEL VLPs and c indicates the comparison between cEDIII and tHBcAg-cEDIII groups.
relation to the entire chimeric particle size should be considered
in future in order to gauge the optimal dose needed for
in vivo study.
In any case, the results presented here highlight potential
limitations to chimeric VLP vaccine development strategies.
The recovered yield of tHBcAg-cEDIII VLPs is considered
relatively low, as it was estimated that less than 10% of the
tHBcAg-cEDIII protein formed soluble particles. Extraction
under denaturing conditions was not attempted, since denaturing
and refolding steps for such a complex structure (an assembly
of 90 or 120 copies of a triple protein fusion) are unlikely
to result in the proper formation of core-like particles. In
this study, the tHBcAg-cEDIII protein was targeted to the
cytosol, since this is the strategy that had previously been
used successfully with tandem cores (Peyret et al., 2015),
whereas, by contrast, the recombinant cEDIII protein alone
was targeted to the endoplasmic reticulum (ER). Subcellular
localization for tHBcAg-cEDIII protein was not attempted
initially due to the concerns that distinct pH conditions
in different plant organelles could abolish VLPs assembly
as shown by van Zyl et al. (2016). Nevertheless, it has
recently been shown that HBcAg VLPs are still capable of
assembly despite localization to ER (Yang et al., 2017). In
fact, accumulation of tHBcAg-cEDIII VLPs in the plant cytosol
may have affected the antigen stability via improper disulphide
bond formation in cEDIII. This issue is highlighted because
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the correct folding of antibody recognition epitope on DENV
EDIII relies upon the disulphide linkage (Suzarte et al., 2014).
Given that the redox environment is highly regulated in the ER
(Ellgaard, 2004), optimal oxidoreductase activity can be achieved
to form proper disulphide bridges. The relatively low antibody
response generated in mice immunized with tHBcAg-cEDIII
VLPs as compared to recombinant cEDIII immunized group
might therefore also be explained by the presence of VLPs with
improper folding produced in the plant cytosol.
Hence, as the way forward, future optimizations to modulate
protein yield and stability at the post-translational level may
include attempting different extraction buffers to improve the
solubility of crude extract as well as targeting the heterologous
protein to a subcellular compartment. Researchers carrying out
the future works would be well-advised to test the pre-immune
sera from each individual mouse in order to increase confidence
in any post-immunization results. The full benefits of VLP
presentation should be explored further, as its three-dimensional
structure has a higher potency to activate cell-mediated immunity
including the cytotoxic T cell response, which is crucial for better
viral clearance as reported by Yang et al. (2017). Besides, since
cEDIII represents a consensus antigen, it would also be of great
interest to test the cross-reactivity of polyclonal responses as
well as the protection levels of tHBcAg-cEDIII VLPs against the
different DENV serotypes.
CONCLUSION
While there has been a previous initiative that used a yeast
system to produce a chimeric VLP-based dengue vaccine
candidate (Arora et al., 2013); development of a plant-
derived vaccine can offer scalability and safety advantages
that revolutionize the accessibility of dengue vaccines (Pang
and Loh, 2017). This is particularly important to address
the alarming burden of dengue disease that has yet to meet
a promising resolution. The adoption of “Tandem Core”
technology was proven to be feasible although there is still
room for improvements. Overall, a successful assembly of VLPs
displaying a consensus dengue antigen has been achieved. The
immunization data have shown that seroconversion to cEDIII is
possible when mice are immunized with tHBcAg-cEDIII VLPs.
The current findings have validated the viability of using a
VLP system as an antigen-presentation platform; this warrants
further investigation into its potential as a next-generation
dengue vaccine.
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